골다공증성 척추 골절 환자에서 생존 분석을 통한 골다공증 약물 복용 지속률과 복용 인자
Medication Persistence for Osteoporosis and Its Related Factor in Patients with Osteoporotic Compression Vertebral Fracture
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Introduction: Osteoporotic vertebral fractures, which account for the largest part of the disease has become important and common diseases. We studied persistence for osteoporosis medication and its related factor in patients with osteoporotic compression vertebral fracture. Methods: A total of 458 patients that visited our outpatient clinic with osteoporotic vertebral fractures and were prescribed with osteoporosis medication at the Seoul Spine Center from January 2010 to February 2014 and were analyzed retrospectively. The male to female ratio was 403: 55 and the mean age was 75 years. Survival analysis was used with the Kaplan-Meier method. Related factor analysis was performed with the log rank test and Cox regression test. Results: The survival rate at 6 months was 52%, 12 months was 40%, 24 months was 28%, and at 3 years it was 25%. There was no difference between the persistent rate according to age. Women demonstrated higher persistent rate than men in significantly. It showed a significant difference between some of the groups in accordance with the dose rate and duration of the drug dose interval. Especially, medication change group had significant higher persistence rate than not changing group. Conclusions: Persistence rate of osteoporosis drugs, decreased rapidly with the passage of time. The patients with changing medication during follow-up had significantly higher persistence ratio than those without it. The persistence rate of osteoporosis medication could be increased through actively solving the problems of the patients, which are associated with taking medication.
Abstract
Introduction: Osteoporotic vertebral fractures, which account for the largest part of the disease has become important and common diseases. We studied persistence for osteoporosis medication and its related factor in patients with osteoporotic compression vertebral fracture. Methods: A total of 458 patients that visited our outpatient clinic with osteoporotic vertebral fractures and were prescribed with osteoporosis medication at the Seoul Spine Center from January 2010 to February 2014 and were analyzed retrospectively. The male to female ratio was 403: 55 and the mean age was 75 years. Survival analysis was used with the Kaplan-Meier method. Related factor analysis was performed with the log rank test and Cox regression test. Results: The survival rate at 6 months was 52%, 12 months was 40%, 24 months was 28%, and at 3 years it was 25%. There was no difference between the persistent rate according to age. Women demonstrated higher persistent rate than men in significantly. It showed a significant difference between some of the groups in accordance with the dose rate and duration of the drug dose interval. Especially, medication change group had significant higher persistence rate than not changing group. Conclusions: Persistence rate of osteoporosis drugs, decreased rapidly with the passage of time. The patients with changing medication during follow-up had significantly higher persistence ratio than those without it. The persistence rate of osteoporosis medication could be increased through actively solving the problems of the patients, which are associated with taking medication.
참고문헌 (23)
- Choi YJ, "The prevalence of osteoporosis in Korean adults aged 50 years or older and the higher diagnosis rates in women who were beneficiaries of a national screening program: the Korea National Health and Nutrition Examination Survey 2008-2009", Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 27, pp.1879~1886 (2012)
- Cramer JA, "Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis", Current Medical Research and Opinion, 21, pp.1453~1460 (2005)
- Barbosa CD, "A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence", Patient Prefer Adherence, 6, pp.39~48 (2012)
- Lars Osterberg, "Adherence to medication", The new england Journal of Medicine (2005)
- Andrade SE, "Methods for evaluation of medication adherence an persistence using automated databases", Pharmacoepidemiology and Drug Safety, 15, pp.565~574 (2006)
- Sunyecz JA, "Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization", Osteoporosis International, 19, pp.1421~1429 (2008)
- Rabenda V, "Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women", Osteoporosis International, 19, pp.811~818 (2008)
- Siris ES, "Adherence to bisphosphonate therapy and fracture rates in osteoporotic women:relationship to vertebral and nonvertebral fractures from 2 US claims databases", Mayo Clinic Proceedings, 81(8), pp.1013~1022 (2006), Elsevier
- Siris ES, "Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe", American Journal of Medicine The, 122, pp.S3~S13 (2009)
- Majumdar SR, "Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial", Osteoporos Int, 18, pp.261~270 (2007)
- Ettinger B, "Alendronate use among 812 women:prevalence of gastrointestinal complaints, noncompliance with patient instructions and discontinuation", J Managed Care Pharm, 4, pp.488~492 (1998)
- Carr AJ, "Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey", Osteoporosis International, 17, pp.1638~1644 (2006)
- Penning-van Beest FJA, "Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis", Clinical Therapeutics, 28, pp.236~242 (2006)
- Gleeson T, "Interventions to improve adherence and persistence with osteoporosis medications:a systematic literature review", Osteoporosis International, 20, pp.2127~2134 (2009)
- Emkey RD, "Improving Compliance and Persistence with Bisphosphonate Therapy for Osteoporosis", Am J Med, 119(4 Suppl 1), pp.S18~24 (2006)
- Cramer JA, "A systematic review of persistence and compliance with bisphosphonates for osteoporosis", Osteoporosis International, 18, pp.1023~1031 (2007)
- Li L, "Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the UK General Practice Research Database", Menopause (2014)
- Clowes JA, "The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial", The Journal of Clinical Endocrinology & Metabolism, 89, pp.1117~1123 (2004)
- Arden N, "Persistence with teriparatide in patients with osteoporosis: the UK experience", Osteoporosis International, 17, pp.1626~1629 (2006)
- Delmas PD, "Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis", The Journal of Clinical Endocrinology & Metabolism, 92, pp.1296~1304 (2007)
- Brankin E, "The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases", Current Medical Research and Opinion, 22, pp.1249~1256 (2006)
- Cotté F-E, "Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis", Osteoporosis International, 21, pp.145~155 (2009)
- Roerholt C, "Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence", Osteoporosis International, 20, pp.299~307 (2009)